Omalizumab, an anti-immunoglobulin E antibody: state of the art
Open Access
- 1 February 2014
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 8, 197-207
Abstract
A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of hospitalizations for asthma attacks. In recent years, some studies have shown that omalizumab is effective also in nonallergic asthma. Effects on the complex signaling mechanisms leading to activation of effector cells and to mediator release may account for this outcome. Indeed, omalizumab has been reported to be effective in a number of IgE-mediated and non-IgE-mediated disorders. Concerning the former, clinical efficacy has been observed in rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, and anaphylaxis. In addition, omalizumab has been demonstrated to be able to prevent systemic reactions to allergen immunotherapy, thus enabling completion of treatment in patients who otherwise would have to stop it. Concerning non-IgE-mediated disorders, omalizumab has been reported to be effective in nasal polyposis, autoimmune urticaria, chronic idiopathic urticaria, physical urticaria, idiopathic angioedema, and mastocytosis. Current indications for treatment with omalizumab are confined to severe allergic asthma. Consequently, any other prescription can only be off-label. However, it is reasonable to expect that the use of omalizumab will be approved for particularly important indications, such as anaphylaxis, in the near future.Keywords
This publication has 102 references indexed in Scilit:
- Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumabJournal of Asthma and Allergy, 2012
- Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disordersClinical and Molecular Allergy, 2011
- Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City ChildrenNew England Journal of Medicine, 2011
- The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and childrenJournal of Asthma and Allergy, 2011
- Omalizumab for severe atopic keratoconjunctivitis: Figure 1BMJ Case Reports, 2010
- A systematic review of economic evaluations of therapy in asthmaJournal of Asthma and Allergy, 2010
- Regulation of Syk kinase and FcRβ expression in human basophils during treatment with omalizumabJournal of Allergy and Clinical Immunology, 2010
- Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosisBMJ Case Reports, 2009
- Anti-IgE treatment of eosinophil-associated gastrointestinal disordersJournal of Allergy and Clinical Immunology, 2007
- Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibodyThorax, 2007